ACONNasdaqServices-Medical LaboratoriesFiscal year ends December 31Also trades as ACONW

Aclarion, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$1.89+0.04 (+2.16%)

Close on Oct 19, 2026

Market cap: $4.65M
P/E (TTM): –
Dividend yield: –

Aclarion, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	0.08	0.05	0.08	0.06	0.06
Cost of Revenue	0.07	0.08	0.08	0.07	0.07
Gross Profit	0.01	-0.04	0.00	0.00	-0.01
Research & Development	1.03	0.89	0.87	1.07	0.79
Selling, General & Admin	6.03	4.59	4.00	4.49	2.16
Selling & Marketing	1.90	0.98	0.76	0.50	0.33
General & Administrative	4.12	3.61	3.25	3.99	1.83
Operating Expenses	7.06	5.47	4.88	5.56	2.94
Operating Income	-7.05	-5.51	-4.88	-5.56	-2.95
Interest Expense	–	0.06	0.11	1.51	0.47
Interest & Investment Income	0.41	0.00	–	–	–
Other Non-Operating Income	-0.18	-1.48	-0.04	-1.51	-2.00
Gain (Loss) on Sale of Assets	–	–	0	0.00	0
Legal Settlements	-0.69	–	–	–	–
Pretax Income	-7.23	-6.99	-4.91	-7.07	–
Income Tax Expense	0	0	0	0	0
Net Income incl. Noncontrolling Interests	-7.24	-7.05	-4.91	-7.48	-4.95
Net Income	-7.23	-6.99	-4.91	-7.07	-4.95
Preferred Dividends	–	–	–	0.42	1.01
Net Income to Common	-7.24	-7.05	-4.91	-7.48	-5.96
EPS (Basic)(per share)	-13.61	-7,478.90	-79,782.00	-177,411.67	-952,468.16
EPS (Diluted)(per share)	-13.61	-7,478.90	-79,782.00	-177,411.67	-952,468.16
Shares Outstanding (Basic, Weighted)(shares)	0.53	0.00	0.00	0.00	0.00
Shares Outstanding (Diluted, Weighted)(shares)	0.53	0.00	0.00	0.00	0.00
EBITDA	-6.82	-5.32	-4.71	-5.42	-2.77

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 21.8%
Operating margin: -11592.1%
Net margin: -10978.5%
Return on equity, FY2025: -104.8%

Financial strength

Current ratio: 16.20
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 1570.5%

Valuation

P/E ratio: –
Price to sales: 55.55
Price to book: 0.27
Dividend yield: –